quinazolines has been researched along with zd 6474 in 540 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 150 (27.78) | 29.6817 |
| 2010's | 348 (64.44) | 24.3611 |
| 2020's | 42 (7.78) | 2.80 |
| Authors | Studies |
|---|---|
| Curwen, JO; Dukes, M; Hennequin, LF; Johnstone, C; Kendrew, J; Ogilvie, DJ; Plé, PA; Stokes, ES; Thomas, AP; Wedge, SR | 1 |
| Bigley, AL; Boffey, SJ; Chester, R; Curry, B; Curwen, JO; Dukes, M; Graham, GA; Hennequin, LF; Hughes, GD; Jackson, JA; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Stokes, ES; Thomas, AP; Valentine, PJ; Wadsworth, PF; Wedge, SR | 1 |
| Carlomagno, F; Ciardiello, F; Fontanini, G; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Tortora, G; Vecchio, G; Vitagliano, D | 1 |
| Rosen, LS | 1 |
| Arteaga, CL | 1 |
| Bianco, AR; Caputo, R; Carlomagno, F; Ciardiello, F; Damiano, V; Fontanini, G; Tortora, G; Troiani, T; Veneziani, BM; Vitagliano, D | 1 |
| Bergh, A; Collin, O; Jonsson, A; Rudolfsson, SH; Wikström, P | 1 |
| Checkley, D; Kendrew, J; Tessier, JJ; Waterton, JC; Wedge, SR | 1 |
| Shiotsu, Y | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; De Vita, F; Melisi, D; Tortora, G; Troiani, T | 1 |
| Bates, D | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Gear, RB; Heffelfinger, SC; LaDow, K; Schneider, J; Warshawsky, D; Yan, M | 1 |
| Carlomagno, F; Fusco, A; Hershman, JM; Melillo, RM; Motti, ML; Nikiforov, YE; Nikiforova, MN; Ryan, AJ; Santoro, M; Viglietto, G; Vitagliano, D | 1 |
| Anaganti, S; Billaud, M; Carlomagno, F; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Vecchio, G | 1 |
| Andersson, U; Bergenheim, AT; Bergh, A; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Bucana, C; Ellis, LM; Fan, F; Liu, W; Mansfield, PF; McCarty, MF; Ryan, AJ; Stoeltzing, O; Wey, J | 1 |
| de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P | 1 |
| Chambers, AF; Ellis, CG; Groom, AC; MacDonald, IC; Mackenzie, LT; Ryan, A; Varghese, HJ | 1 |
| Shi, W; Siemann, DW | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T | 1 |
| Brave, S; Kendrew, J; Stratford, IJ; Telfer, BA; Wedge, SR; Whittaker, L; Williams, KJ | 1 |
| Conaway, M; Gulding, K; Nicholson, B; Theodorescu, D; Wedge, SR | 1 |
| Carlomagno, F; Santoro, M | 1 |
| Bianco, R; Bianco, RA; Ciardiello, F; De Vita, F; Fontanini, G; Martinelli, E; Morgillo, F; Romano, M; Tortora, G; Troiani, T; Tuccillo, C | 1 |
| Barge, A; Baselga, J; Miller, KD; Rowbottom, J; Sledge, G; Trigo, JM; Wheeler, C | 1 |
| Baker, CH; Beaudry, P; Folkman, J; Force, J; Heymach, JV; Johnson, BE; Naumov, GN; Ryan, A; Soker, S; Wang, A | 1 |
| Cagan, R; Ryan, A; Vidal, M; Wells, S | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Drevs, J; Esser, N; Konerding, MA; Ogilvie, DJ; Ryan, AJ; Wedge, SR; Wolloscheck, T | 1 |
| Barge, A; Basser, R; de Boer, R; Eckhardt, SG; Green, M; Holden, SN; Hurwitz, HI; Rischin, D; Rosenthal, MA; Wheeler, C | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Heymach, JV | 1 |
| Ryan, AJ; Wedge, SR | 1 |
| Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Raben, D; Ryan, A; Tortora, G | 1 |
| Awad, H; Hurwitz, H; Klitzman, B; Ko, J; Ross, J | 1 |
| Lee, D | 1 |
| Soff, G; Zakarija, A | 1 |
| Buolamwini, JK; Kamath, S | 1 |
| Bigner, DD; Dimery, I; Friedman, HS; Graner, MW; Kaipainen, A; Keir, ST; Kieran, MW; Laforme, A; McLendon, RE; Rasheed, BK; Reardon, DA; Rich, JN; Ryan, AJ; Sathornsumetee, S; Wang, L; Wheeler, C | 1 |
| Antonaci, S; Azzariti, A; Giannelli, G; Paradiso, A; Porcelli, L; Sgarra, C | 2 |
| Edakuni, N; Goto, H; Kakiuchi, S; Matsumori, Y; Muguruma, H; Nakataki, E; Ryan, A; Sone, S; Tomimoto, H; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Bianco, C; Ciardiello, F; Dimery, I; Frederick, B; Gustafson, D; Raben, D | 1 |
| Cascone, T; Ciardiello, F; Gridelli, C; Morelli, MP; Troiani, T | 1 |
| Cazzaniga, S; Gambacorti-Passerini, C; Mologni, L; Papinutto, E; Sala, E | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Govindan, R; Morgensztern, D | 1 |
| Bradshaw-Pierce, EL; Gustafson, DL; Merz, AL; Zirrolli, JA | 1 |
| Bianco, R; Cascone, T; Ciardiello, F; De Pacido, S; Eckhardt, SG; Fontanini, G; Morelli, MP; Normanno, N; Romano, M; Tortora, G; Troiani, T; Tuccillo, C; Veneziani, BM | 1 |
| Bozec, A; Fischel, JL; Milano, G | 1 |
| Brazelle, WD; Shi, W; Siemann, DW | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Dong, RP; Eisenhauer, E; Kovacs, MJ; Marcellus, D; Mathews, S; Meyer, RM; Reece, DE | 1 |
| Ciardiello, F; Eckhardt, SG; Lockerbie, O; Morrow, M; Troiani, T | 1 |
| McNeil, C | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM | 1 |
| Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Taguchi, T; Yang, Y; Zhu, WG | 1 |
| Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A | 1 |
| Rich, JN; Sathornsumetee, S | 1 |
| Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T | 1 |
| Bergh, A; Halin, S; Hammarsten, P; Henriksson, R; Rudolfsson, SH; Wikstöm, P | 1 |
| Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y | 1 |
| Herbst, RS | 1 |
| Herbst, RS; Heymach, JV; O'Reilly, MS; Onn, A; Ryan, AJ | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Komaki, R; Langley, RR; O'Reilly, MS; Onn, A; Ryan, AJ; Shibuya, K; Shitani, T; Wu, W | 1 |
| Schneider, BP; Sledge, GW | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Kuwayama, Y; Nishioka, C; Taguchi, H; Takeshita, A; Tasaka, T; Togitani, K; Yang, J; Yang, Y | 1 |
| Frederick, B; Gustafson, DL; Merz, AL; Raben, D | 1 |
| Ballabh, P; Braun, A; Csiszar, A; Goldman, SA; Hu, F; Lou, N; Nedergaard, M; Rivera, A; Smith, K; Ungvari, Z; Xu, H | 1 |
| Sequist, LV | 1 |
| Hanna, N | 1 |
| Ebi, H; Fujisaka, Y; Horiike, A; Jiang, H; Kawada, K; Minami, H; Murakami, H; Saijo, N; Sasaki, Y; Shimoyama, T; Shinkai, T; Tahara, M; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Bradley, DP; Checkley, D; Kendrew, J; Kuribayashi, H; Tessier, JL; Waterton, JC; Wedge, SR | 1 |
| Kiselyov, AS; Milligan, D; Ouyang, X | 1 |
| Huang, W; Liu, QQ; Liu, R; Wu, J; Xiao, X; Zeng, M; Zhao, P; Zheng, L; Zhou, J; Zhu, X | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Ahlman, H; Bernhardt, P; Jansson, S; Johanson, V; Kölby, L; Nilsson, O; Persson, F; Stenman, G; Stridsberg, M; Swärd, C; Wängberg, B | 1 |
| Kibble, A | 1 |
| Hanrahan, EO; Heymach, JV | 1 |
| Advani, A; Advani, SL; Cox, AJ; Gilbert, RE; Gow, RM; Kelly, DJ; Marsden, PA; Marshall, SM; Rakoczy, PE; Steer, BM; Thai, K; White, KE; Zhang, Y | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Belani, CP; Bodrogi, I; Csada, E; Gadgeel, S; Herbst, RS; Heymach, JV; Hou, J; Johnson, BE; Kennedy, SJ; Pesek, M; Prager, D; Roubec, J; Spásová, I | 1 |
| Alam, Y; Arnold, AM; Butts, C; Chan, A; Ding, K; Djurfeldt, M; Ellis, P; Findlay, B; Goss, G; Gregg, R; Langmuir, P; Lee, CW; Meharchand, J; Seymour, L; Shepherd, F; Smylie, M; Ung, Y; Whitehead, M | 1 |
| Ang, K; Herbst, RS; Itasaka, S; Jürgensmeier, JM; Komaki, R; Milas, L; O'Reilly, MS; Ryan, A; Shibuya, K; Shintani, T | 1 |
| Lou, L; Mi, Y | 1 |
| Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
| Ballabh, P; Braun, A; Chander, P; Csiszar, A; Hu, F; Kocherlakota, P; Nedergaard, M; Siegel, D; Ungvari, Z; Xu, H | 1 |
| Freshney, RI | 1 |
| Claes, A; Gambarota, G; Hamans, B; Heerschap, A; Leenders, W; Maass, C; van Tellingen, O; Wesseling, P | 1 |
| Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Beaudry, P; Folkman, J; Heymach, J; Nilsson, M; Poon, D; Prox, D; Rioth, M; Ryan, A; Ryeom, S; Xu, L; Zweidler-Mckay, P | 1 |
| Giordano, S; Petrelli, A | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S | 1 |
| Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Lee, CB; Socinski, MA | 1 |
| Buhl, R; Fischer, B | 1 |
| Sherman, SI | 2 |
| Gettinger, S | 1 |
| Natale, RB | 1 |
| Doody, JF; Hadari, YR; Katoch-Rouse, R; Kim, K; Kiselyov, AS; Ouyang, X; Piatnitski Chekler, EL; Sherman, D; Wang, Y | 1 |
| Fukumura, D; Hoshida, T; Jain, RK; Kozak, KR; Kuo, AH; Liao, S; Lobo, J; Padera, TP | 1 |
| Albini, A; Benelli, R; Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; De Falco, S; Garofalo, S; Gelardi, T; Melisi, D; Rosa, R; Ryan, A; Tarallo, V; Tortora, G | 1 |
| Kawabe, J; Ohsaki, Y; Osanai, S; Sasaki, T; Shibukawa, K; Tanno, S | 1 |
| Chen, WT; Cheung, M; Choi, S; El-Naggar, AK; Jasser, SA; Mao, L; Myers, JN; Ryan, AJ; Sano, D; Zhao, M | 1 |
| Bolshakov, S; Dicker, A; Korchin, B; Lahat, G; Lazar, A; Lev, D; Merritt, W; Nguyen, T; Pollock, RE; Ren, W; Sood, A; Wei, C | 1 |
| Bradshaw-Pierce, EL; Gustafson, DL; Raben, D; Steinhauer, CA | 1 |
| Döme, B; Magyar, M | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Gibbs, P; Godwood, A; Michael, M; Oliver, S; Smith, R; Tebbutt, N | 1 |
| Anaganti, S; Carlomagno, F; Guida, T; Kjaer, S; McDonald, NQ; Provitera, L; Ryan, AJ; Santoro, M | 1 |
| Guo, S; Huang, W; Zhang, Y | 1 |
| de Boer, R; Godwood, A; Humblet, Y; Milenkova, T; Nogová, L; Ruffert, K; Smith, R; Vansteenkiste, J; Wolf, J | 1 |
| Balagtas, C; Bohlen, P; Doody, JF; Duncton, MA; Hadari, YR; Katoch-Rouse, R; Kawakami, JK; Kiselyov, AS; Kussie, P; Milligan, DL; Mitelman, S; Patel, SN; Piatnitski Chekler, EL; Rolster, RL; Sherman, D; Smith, LM; Surguladze, D; Tonra, JR; Wang, Y; Wong, WC | 1 |
| Godwood, A; Oliver, S; Peeters, M; Saunders, MP; Smith, R; Van Cutsem, E; Wilson, R | 1 |
| Bemis, LT; Flaig, TW; Li, Y; McCoach, C; Raben, D; Su, LJ; Varella-Garcia, M | 1 |
| Holmgren, L; Lu, L; Samén, E; Stone-Elander, S; Tegnebratt, T; Thorell, JO | 1 |
| Hirohashi, S; Kasai, S; Kokubu, A; Ochiya, T; Ojima, H; Shibata, T; Yoshikawa, D | 1 |
| Bodkin, D; Capó, A; Eberhardt, WE; Germonpré, P; Govindan, R; Kennedy, SJ; Natale, RB; Ranson, M; Rizvi, NA; Sleckman, BG; Stockman, PK | 1 |
| Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Horn, L; Sandler, AB | 1 |
| Chen, LM; Dai, CL; Fu, LW; Li, YH; Liang, YJ; Mi, YJ; Tao, LY; To, KK; Wang, F; Yan, YY; Yang, AK; Zhang, X; Zheng, LS | 1 |
| Chen, JM; Huang, W; Jia, HY; Tan, L; Wu, JX; Yan, HJ; Yang, SP; Zeng, YX; Zhu, XF | 1 |
| Abratt, RP; Bodrogi, I; Federico, MH; Horti, J; Pover, GM; Sanders, N; Stenzl, A; Widmark, A | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Hanrahan, EO; Herbst, RS; Heymach, JV; Johnson, BE; Kennedy, SJ; Langmuir, P; Mann, H; Natale, RB; Ryan, AJ | 1 |
| Ichihara, E; Kiura, K; Ogino, A; Ohashi, K; Osawa, M; Takigawa, N; Tanimoto, M | 1 |
| Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M | 1 |
| Fine, HA; Smith, JA; Yeh, S | 1 |
| Norris, CM; Ryan, A; Shi, W; Siemann, DW | 1 |
| Chang, CH; Chang, JW; Hui, CY; Yang, CH | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Addo-Yobo, SO; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Hampton, T | 1 |
| Fine, HA; Kong, HH; Stern, JB; Turner, ML | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V | 1 |
| Ansiaux, R; Dewever, J; Feron, O; Gallez, B; Grégoire, V; Jordan, BF | 1 |
| Campiglia, P; De Falco, V; Fenzi, G; Illario, M; Monaco, S; Pastore, L; Rossi, G; Rusciano, MR; Salzano, M; Santoro, M; Sapio, MR; Vitale, M | 1 |
| Du, DZ; Hanrahan, EO; Heymach, JV; Johnson, BE; Kim, ES; Langmuir, P; Lee, JJ; Lin, HY; McKee, KS; Ryan, AJ; Tran, HT; Yan, S | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Gagel, RF; Gosnell, JE; Krebs, A; Moley, J; Pfister, D; Schlumberger, M; Skinner, M; Sosa, JA; Vasselli, J; Wells, SA | 1 |
| Annunziata, CM; Calvo, K; Choyke, P; Kimm, D; Kohn, EC; Kotz, H; Minasian, L; Steinberg, SM; Walker, AJ; Wood, BJ; Yu, M | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Dash, R; Fisher, PB; Mandal, M; Mazumdar, A; Sarkar, D; Sarkar, S | 2 |
| Hirte, H; Hotte, SJ; Kavsak, PA | 1 |
| Nair, BC; Vadlamudi, RK | 1 |
| Fang, W; Heymach, JV; Nilsson, MB; Palla, S; Zage, PE; Zeng, L; Zweidler-McKay, PA | 1 |
| He, BF; Luo, RC; Miao, JX; Ruan, J; Shen, J; Zhao, P; Zheng, H | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Haddad, R; Krebs, A; Paz-Ares, L; Robinson, BG; Vasselli, J | 1 |
| Cheng, SY; Chiou, SH; Feng, H; Hu, B; Lieberman, FS; Liu, KW; Ma, HI; Sarkaria, JN; Schornack, PA; Sengar, RS; Wiener, EC; Yiin, JJ | 1 |
| Brekken, RA; Carney, DN; Korpanty, G; Smyth, E; Sullivan, LA | 1 |
| Chan, AW; di Tomaso, E; Jain, RK; Kamoun, WS; Lahdenranta, J; McClatchey, AI; Plotkin, SR; Wong, HK | 1 |
| Huang, W; Jia, H; Ma, J; Tan, L; Wu, J; Yan, H; Yang, S; Zeng, M; Zhu, X; Zuo, Y | 1 |
| Biesma, B; Eberhardt, WE; Germonpré, P; Herbst, RS; Heymach, JV; Ichinose, Y; Johnson, BE; Kabbinavar, F; Kennedy, SJ; Langmuir, P; Li, L; Qin, S; Saijo, N; Sun, Y; Tada, H; Wang, J; Zhang, L; Zhou, C | 1 |
| Govindan, R; Stinchcombe, TE | 1 |
| Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M | 1 |
| Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Langmuir, P; Martin, P; Molz, KH; Oliver, S; Read, J; Smith, R; Weil, A | 1 |
| Flaig, TW; Li, Y; Su, LJ; Yang, X | 1 |
| Alferez, DG; Goodlad, RA; Ryan, AJ; Wilkinson, RW; Wright, NA | 1 |
| Antti, H; Bergenheim, AT; Henriksson, R; Johansson, M; Sandström, M; Wibom, C | 1 |
| Chen, X; Hoffman, L; Lee, TY; Ryan, AJ; Tai, JH; Tessier, J | 1 |
| Andreasson, I; Boér, K; Láng, I; Llombart-Cussac, A; Murray, E; Pover, GM; Sanders, N; Vivanco, GL | 1 |
| Baker, JN; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Gilbertson, RJ; Kaste, SC; Kocak, M; Leung, W; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panandiker, AP; Rowland, C; Stewart, CF; Tagen, M | 1 |
| Carlomagno, F; Chiappetta, G; Ciardiello, F; Coluzzi, S; De Falco, V; Fagin, JA; Ryan, AJ; Santoro, M; Tamburrino, A; Tortora, G; Troncone, G; Vitagliano, D | 1 |
| Bryce, J; Carillio, G; Carotenuto, P; Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; La Rocca, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Doçi, CL; Hasina, R; Lingen, MW; Mankame, TP; Wroblewski, K; Zhou, G | 1 |
| Burtness, B; Psyrri, A | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| DeRyckere, D; Gore, L; Macy, ME | 1 |
| Daroczi, B; Dicker, AP; Lawrence, YR; Liu, Y; Wachsberger, PR; Xu, X | 1 |
| Amadori, A; Ancona, E; Balza, E; Borsi, L; Crescenzi, M; Esposito, G; Indraccolo, S; Persano, L; Ruol, A; Zulato, E | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Chilin, A; Conconi, MT; Guiotto, A; Marzaro, G; Parnigotto, PP; Tommasini, M; Tonus, F; Urbani, L; Zanusso, I | 1 |
| Goto, H; Li, Q; Nakataki, E; Nishioka, Y; Ogino, H; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yano, S | 1 |
| Bankson, JA; Chen, Y; Frederick, MJ; Galer, CE; Gule, MK; Henderson, YC; Jasser, SA; Lai, SY; Milas, ZL; Myers, JN; Sano, D; Schwartz, DL; Zhao, M; Zhou, G | 1 |
| Benz, MR; Bockisch, A; Czernin, J; Damoiseaux, RD; Hartung, V; Hildebrandt, IJ; Laing, RE; Phelps, ME; Walter, MA; Weber, WA | 1 |
| Allen, D; Cao, L; Chen, A; Chen, H; Choyke, P; Collins, J; Doroshow, JH; Gutierrez, ME; Horneffer, YR; Juwara, L; Kim, YS; Kummar, S; Melillo, G; Murgo, AJ; Trepel, J; Turkbey, IB; Yu, Y | 1 |
| Barlesi, F; Tomasini, P | 1 |
| Abratt, RP; Arrieta, Ó; Blackhall, FH; Chan, V; de Boer, RH; de Marinis, F; Gottfried, M; Langmuir, P; Milenkova, T; Raats, J; Read, J; Vansteenkiste, JF; Wolf, J; Yang, CH | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Hanna, EY; Heymach, J; Matsumoto, F; Milas, L; Molkentine, DP; Myers, JN; Papadimitrakopoulou, V; Sano, D; Takahashi, Y; Valdecanas, DR; Zhao, M | 1 |
| Friedrich, MJ | 1 |
| Takami, HE | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Duvauchelle, T; Kennedy, SJ; Martin, P; Oliver, S; Read, J; Robertson, J | 1 |
| Brooks, S; Kong, HH; Linehan, WM; Srinivasan, R | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Beckman, JA; Burstein, HJ; Dallabrida, SM; Hannagan, K; Ismail, NS; Mayer, EL; Redline, WM; Rupnick, MA | 1 |
| Acheson, KL; Baker, D; Barry, ST; Brave, SR; Hickinson, DM; Howard, Z; Jackson, L; James, NH; Lovick, SC; Marshall, GB; Odedra, R; Ratcliffe, K; Ryan, AJ; Smith, NR; Speake, G; Wainwright, A; Wilkinson, RW | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Gao, M; Lola, CM; Miller, KD; Sledge, GW; Wang, M; Zheng, QH | 1 |
| Brierley, R | 1 |
| Guan, Z; Jiang, Y; Li, S; Liao, H; Martin, PD; Smith, R; Zhan, J; Zhang, L; Zhang, Y; Zou, BY | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Hu, MI | 1 |
| Baudin, E; Borget, I; Brailly-Tabard, S; Brassard, M; Chanson, P; Leboulleux, S; Neraud, B; Salenave, S; Schlumberger, M; Trabado, S; Young, J | 1 |
| Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Commander, H; Perry, C; Whiteside, G | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
| Bai, F; Broniscer, A; Johnson, J; Stewart, CF; Wang, F; Yang, L | 1 |
| de Boer, RH; Wong, HL | 1 |
| Kennedy, KC; Qurollo, BA; Rose, BJ; Thamm, DH | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Alecci, C; Assaraf, YG; Destro, A; Giancola, F; Gianoncelli, L; Giovannetti, E; Leon, LG; Lorenzi, E; Peters, GJ; Roncalli, M; Santoro, A; Smid, K; Zucali, PA | 1 |
| Ahn, J; Hyon, JY; Lee, JH; Wee, WR | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Baudin, E; Dralle, H; Elisei, R; Fagin, JA; Gagel, RF; Jarzab, B; Langmuir, P; Read, J; Robinson, BG; Ryan, AJ; Santoro, M; Schlumberger, MJ; Vasselli, JR; Wells, SA | 1 |
| Rischin, D; Solomon, B | 1 |
| Langenkamp, E; Leenders, WP; Molema, G; Moorlag, HE; St Croix, B; Zwiers, PJ | 1 |
| Arpin, D; Ernesto, S; Nesme, P; Pérol, M | 1 |
| Langmuir, PB; Yver, A | 1 |
| Houvras, Y | 1 |
| Benoit, A; Cho, TH; de la Fouchardière, C; Derbel, O; Duplomb, S; Mechtouff-Cimarelli, L; Peix, JL | 1 |
| Ji, XL; Li, YL; Lin, MS; Song, SH; Tang, LD; Wu, CF; Yu, B | 1 |
| Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY | 1 |
| Clarke, D; Giles, P; Hutchison, M; Kennedy, SJ; Martin, P; Oliver, S; Partridge, E | 1 |
| Goozner, M | 1 |
| Chao, Y; Cheng, AL; Hsieh, RK; Hsieh, TY; Hsu, C; Huang, WT; Huo, TI; Hwang, WS; Meng, R; Yang, TS; Yu, CW | 1 |
| Gubish, CT; Henry, C; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Ahn, SM; Christopoulos, A; Gooding, WE; Grandis, JR; Kim, S; Klein, JD | 1 |
| Asaka, R; Hamanaka, W; Hatano, S; Ishikawa, Y; Lim Choi, Y; Mano, H; Nakagawa, K; Ninomiya, H; Okumura, S; Sakata, S; Satoh, Y; Soda, M; Suzuki, R; Takeuchi, K; Togashi, Y; Uehara, H | 1 |
| Arai, Y; Chiku, S; Enari, M; Furuta, K; Harris, CC; Haugen, A; Hiramoto, M; Ichikawa, H; Iwakawa, R; Kohno, T; Nammo, T; Ogawa, S; Ogiwara, H; Oike, T; Okayama, H; Sakamoto, H; Schetter, AJ; Sekine, I; Shibata, T; Shimada, Y; Skaug, V; Totoki, Y; Tsuda, H; Tsuta, K; Watanabe, S; Yamanaka, I; Yasuda, K; Yokota, J; Yoshida, T | 1 |
| Guo, L; Liu, Z; Meng, Q; Shi, H; Tang, J; Xu, L; Zhu, Y | 1 |
| Almeida, MQ; Hoff, AO | 1 |
| Bai, J; Chang, Y; Ding, C; He, J; Kang, E; Tang, L; Wu, S; Xu, X; Yue, L; Zang, J | 1 |
| Blajman, CR; Chen, YM; Emerson, L; Hirsh, V; Langmuir, P; Lee, JS; Manegold, C; Park, K; Perng, RP; Qin, S | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Bai, C; He, J; Li, H; Qin, Y; Song, H; Wang, C; Wei, L; Wu, C; Wu, M; Xu, J; Zhang, X; Zhu, T | 1 |
| Döme, B; Török, S | 1 |
| Tao, L; Yang, F; Zhu, B; Zhuo, W | 1 |
| Bénard, J; Bidart, JM; Farinotti, R; Forestier, F; Gil, S; Jovelet, C | 1 |
| Jo, MY; Joo, KM; Kim, HH; Kim, MH; Kim, Y; Kim, YG; Lee, SJ; Nam, DH | 1 |
| Pashankar, FD; Rapkin, L | 1 |
| Antalffy, G; Hegedüs, C; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Settleman, J; Szakács, G; Truta-Feles, K; Váradi, A; Várady, G | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Baudin, E; Chougnet, C; Leboulleux, S; Massicotte, MH; Nascimento, CL; Schlumberger, M | 1 |
| Boult, JK; Elvin, P; Gilmour, LD; Halliday, J; Jacobs, V; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Guérin, O; Lattanzio, L; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G; Monteverde, M; Ortholan, C; Pagès, G; Sudaka, A; Tonissi, F | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Koga, H; Masuda, H; Nakamura, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Balakrishnan, S; Booth, B; Chattopadhyay, S; Dorsam, R; Duan, J; Garnett, C; Gehrke, B; Ghosh, D; Ibrahim, A; Justice, R; Kim, G; Liu, Q; Maher, VE; Marathe, A; Miksinski, SP; Moon, YJ; Murgo, A; Pazdur, R; Sarker, H; Skarupa, L; Song, P; Tang, S; Thornton, K; Verbois, L; Wilson, W; Zhu, H | 1 |
| Chu, CT; Kim, ES; Sada, YH | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Dempsey, EC; Fagan, KA; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Frampton, JE | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Jia, HY; Li, J; Wang, ZY; Wu, XM; Zhou, Q | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Bible, KC | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Frampton, JE; Keating, GM; Lyseng-Williamson, KA | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Bottai, G; Santarpia, L | 1 |
| Burstein, HJ; Chen, WY; Downing, SR; Gelman, R; Hannagan, K; Isakoff, SJ; Klement, G; Mayer, EL; Winer, EP | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Dolgin, E | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; McNeill, KA; Shih, J; Sul, J | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Baum, RP; Briest, F; Grabowski, P; Hörsch, D; Kulkarni, HR; Zaknun, JJ; Zeitz, M | 1 |
| Liu, HB; Lv, TF; Shi, Y; Song, Y; Xiao, YY; Yuan, DM; Zhan, P | 1 |
| Campbell, MJ; Gosnell, J; Seib, CD | 1 |
| Chau, NG; Haddad, RI | 1 |
| Arnault, JP; Baudin, E; Brassard, M; Giacchero, D; Maksimovic, L; Mateus, C; Ramacciotti, C; Robert, C; Schlumberger, M; Tomasic, G; Wechsler, J | 1 |
| Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D | 1 |
| Ichihara, E; Kataoka, I; Kiura, K; Minami, D; Ochi, N; Ohashi, K; Takeda, H; Takigawa, N; Tanimoto, M | 1 |
| Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
| Cunnane, ME; Randolph, GW; Ross, DS; Sadow, PM; Wirth, LJ | 1 |
| Broniscer, A; Hillenbrand, CM; Kocak, M; Loeffler, RB; Sedlacik, J; Winchell, A | 1 |
| Bidart, JM; Broutin, S; Deroussent, A; Farinotti, R; Gil, S; Jovelet, C; Paci, A | 1 |
| Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J | 1 |
| Burttet, LM; Cerski, MR; Dora, JM; Maia, AL; Scheffel, RS; Siqueira, DR | 1 |
| Park, JI; Starenki, D | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Monneret, C | 1 |
| Antoun, S; Baracos, VE; Baudin, E; Borget, I; Broutin, S; Deroussent, A; Leboulleux, S; Massicotte, MH; Paci, A; Schlumberger, M | 1 |
| Adelstein, DJ; Bokar, JA; Dowlati, A; Fu, P; Halmos, B; Jia, Y; Juergens, R; Rodal, MB | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Esumi, H; Goto, K; Ishii, G; Kohno, T; Makinoshima, H; Matsumoto, S; Matsushima, K; Mimaki, S; Ochiai, A; Shibata, T; Suzuki, A; Suzuki, M; Suzuki, Y; Tsuchihara, K; Tsuta, K; Yoh, K | 1 |
| Alden, CM; Blumenschein, GR; Davis, SE; Herbst, R; Heymach, J; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Tang, X; Tran, H; Tsao, AS; Wistuba, I | 1 |
| Aebi, S; Diebold, J; Gautschi, O; Hirschmann, A; Keller, FA; Strobel, K; Zander, T | 1 |
| Durante, C; Filetti, S; Paciaroni, A; Plasmati, K; Trulli, F | 1 |
| Banaszynski, ME; Kolesar, JM; Ton, GN | 1 |
| Aisner, J; Dakhil, SR; Manola, JB; Schiller, JH; Sovak, MA; Stella, PJ | 1 |
| Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S | 1 |
| Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC | 1 |
| Alafuzoff, I; Bergqvist, M; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, F; Lennartsson, J; Navani, S; Pontén, F; Popova, S; Sooman, L; Tsakonas, G | 1 |
| Fang, W; Li, A; Luo, S; Niu, X; Ruan, J; Shen, J; Tian, G; Zhao, P; Zheng, H | 1 |
| Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Dall'acqua, S; Salvador, A; Vedaldi, D | 1 |
| Chen, S; Ding, W; Gu, J; Kim, S; Li, X; Pan, M; Tian, W; Zhang, L; Zheng, L | 1 |
| Baudry, C; Groussin, L; Paepegaey, AC | 1 |
| Postel-Vinay, S; Schlumberger, M; Soria, JC | 1 |
| du Bois, A; Elser, G; Harter, P; Hilpert, F; Kimmig, R; Kurzeder, C; Rau, J; Sehouli, J | 1 |
| Rodrigues, AD; Shen, H; Yang, Z; Zhang, Y; Zhao, W | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Cagan, RL; Das, TK | 1 |
| Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Kelly, DJ; Thai, K; Zhang, Y | 1 |
| Ahn, JS; Ahn, MJ; Cho, EK; Kang, ES; Kang, JH; Kim, SW; Lee, DH; Lee, GW; Lee, JS; Lee, JW; Lee, KH; Park, K; Sun, JM | 1 |
| Kim, YS; Li, F; Li, Z; O'Neill, BE | 1 |
| Mandal, M; Rajput, S; Sarkar, S; Tripathi, AK | 1 |
| Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Bidart, JM; Broutin, S; Caillou, B; Commo, F; De Koning, L; Dubois, T; Dupuy, C; Lacroix, L; Marty-Prouvost, B; Ryan, AJ; Schlumberger, M; Talbot, M | 1 |
| Alghamdi, W; Cooper, MR; Shaheen, DJ; Steinberg, M; Yi, SY | 1 |
| Cohen, MS; Sim, MW | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Das, S; Mandal, M; Mitra, A; Pradhan, R; Rajput, S | 1 |
| Ding, X; Duan, W; Jin, X; Sun, Y; Wang, N; Wang, S; Xiang, L; Zhao, Z | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Bao, J; Dai, Z; Lan, Y; Tu, W; Wei, T; Zhao, B | 1 |
| Anagnostis, P; Karras, S; Krassas, GE | 1 |
| Askeland, RW; Cyr, AR; De Andrade, JP; Kulak, MV; Park, JM; Spanheimer, PM; Sugg, SL; Thomas, A; Weigel, RJ; Woodfield, GW | 1 |
| Balis, FM; Derdak, J; Fox, E; Kebebew, E; Lodish, MB; Nella, AA; Quezado, MM; Stratakis, CA; Whitcomb, PO; Widemann, BC | 1 |
| Azad, AA; Beardsley, EK; Chi, KN; Chin, J; Ellard, SL; Hotte, SJ; Klotz, L; Kollmannsberger, C; Mukherjee, SD | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Brun, P; Dall'Acqua, S; Salvador, A; Vedaldi, D | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Ito, K; Sugino, K; Takami, H | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Alden, CM; Bashoura, L; Eapen, GA; Faiz, SA; Herbst, RS; Hong, WK; Jack Lee, J; Jimenez, CA; Liu, DD; Marom, EM; Massarelli, E; Mino, B; Morice, RC; Onn, A; Tran, HT; Wistuba, II | 1 |
| Califaretti, N; Chia, SK; Clemons, MJ; Cochrane, B; Dent, RA; Levine, MN; Parpia, S; Pond, GR; Pritchard, KI; Rayson, D; Robidoux, A; Song, X; Warr, D | 1 |
| Beuschel, SL; Hillegass, JM; MacPherson, MB; Macura, SL; Miller, JM; Mossman, BT; Perkins, TN; Sayan, M; Shukla, A; Thompson, JK | 1 |
| Ladizinski, B; Sankey, C | 1 |
| Cohen, PR; Jalalat, SZ | 1 |
| Herbst, RS; Heymach, JV; Johnson, BE; Lockwood, SJ; Ryan, AJ | 1 |
| Imai, T; Ishigame, T; Kohno, T; Kumamoto, K; Saito, M; Tsuta, K | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Frezzetti, D; Gallo, M; Maiello, MR; Morabito, A; Normanno, N; Perrone, F | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Fang, Y; Febles, NK; Ferrie, AM | 1 |
| Caro-Gutiérrez, D; Floristán Muruzábal, MU; Franco, AP; Gómez de la Fuente, E; López Estebaranz, JL | 1 |
| Cabanillas, ME; Hu, MI; Jimenez, C | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Baudin, E; Chougnet, CN; Leboulleux, S; Schlumberger, M | 1 |
| Jarzab, B; Krajewska, J | 1 |
| Chen, CR; Cohen, EW; Frank, SJ; Heymach, JV; Hirsch, FR; Jimeno, A; Lin, H; Lowe, ES; Myers, JN; Nedzi, L; Papadimitrakopoulou, VA; Raben, D; Tran, HT; Vasselli, JR | 1 |
| Bastida, CC; Falchook, GS; Gaido, L; Jackson, T; Karp, DD; Miller, VA; Ordóñez, NG; Stephens, PJ | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Hong, T; Wang, C; Wang, F; Xia, L; Yang, S; Yang, Z | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Bellmunt, J; Choueiri, TK; Di Lorenzo, G; Federico, P; Mullane, S; Necchi, A; Pond, GR; Qu, AQ; Rosenberg, JE; Sonpavde, G | 1 |
| Kaelin, WG | 1 |
| Chen, V; Crooks, DR; Ghosh, S; Krishna, MC; Liao, PJ; Linehan, WM; Mannes, PZ; Matsumoto, S; Merino, M; Mitchell, JB; Neckers, L; Pendergast, AM; Ricketts, CJ; Rouault, TA; Sourbier, C; Srinivasan, R; Srivastava, G; Vocke, CD; Wei, MH; Yang, Y | 1 |
| Batchelor, TT; Beroukhim, R; Betensky, RA; Chheda, MG; Chi, AS; Drappatz, J; Eichler, AF; Gerstner, ER; Hochberg, FH; Norden, AD; Wen, PY; Yang, D | 1 |
| Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A | 1 |
| Ghosh, G; Guo, B; Wu, Y | 1 |
| Bardet, S; Bonichon, F; Borget, I; Chauffert, B; Chougnet, CN; Criniere, L; de la Fouchardiere, C; Drui, D; Leboulleux, S; Niccoli, P; Rohmer, V; Schlumberger, M; Schneegans, O; Schvartz, C; Zanetta, S | 1 |
| Gianni, C; Loffi, M; Lombardi, F; Toffetti, L | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Cai, N; Chen, X; Kong, X; Liu, P; Xu, L; Zhang, Y; Zhou, Y; Zou, H | 1 |
| Fan, ZW; Li, J; Liu, Y; Xu, GG | 1 |
| Bigley, G; Blockley, L; Cresswell, C; Dale, A; Davies, A; de Boer, R; Donald, E; Elvin, P; Fan, S; Fu, H; Gladwin, A; Gray, N; Harrod, G; Herbst, RS; Ji, Q; Lee, JS; Morten, J; Platt, A; Read, J; Stevens, J; Su, X; Vasselli, J; Williams, V; Womack, C; Ye, Q; Zhang, T; Zheng, L | 1 |
| Curry, JL; Goldstein, J; Patel, AB; Piha-Paul, S; Subbiah, V | 1 |
| Kohno, T; Makinoshima, H; Matsushima, K; Sugano, S; Suzuki, A; Suzuki, Y; Tsuchihara, K | 1 |
| Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET | 1 |
| Del Giudice, P; Delord, JP; Hubiche, T; Roché, H; Sibaud, V; Tournier, E | 1 |
| Karedan, T; Perez, CA; Wang, E | 1 |
| Ali, SM; Berry, J; Cascone, T; Guha-Thakurta, N; Heymach, JV; McMahon, C; Miller, V; Pai, S; Roxas, M; Subbiah, IM; Subbiah, V; Tang, Z | 1 |
| Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X | 1 |
| Fassnacht, M; Kreissl, MC; Mueller, SP | 1 |
| Antonelli, A; Benvenga, S; Di Bari, F; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Spisni, R | 1 |
| Cowan, N; Keiser, J | 1 |
| Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Bueno, F; Cross, G; Lucas, S; Pitoia, F; Schmidt, A | 1 |
| Alias, Z; Feroz, SR; Kabir, MZ; Mohamad, SB; Mukarram, AK; Tayyab, S | 1 |
| Covell, LL; Ganti, AK | 1 |
| Bradshaw, N; Davidson, R; MacGregor, FB; Narayanan, VK; Reed, N; Ronghe, M; Shaikh, MG; Welbury, R | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Buck, AK; Grelle, I; Hänscheid, H; Herrmann, K; Higuchi, T; Lapa, C; Lückerath, K; Muegge, DO; Reiners, C; Schmid, JS; Werner, RA | 1 |
| Cui, Y; Li, X; Liu, H; Wang, D; Xu, T; Yin, B; Zhang, C; Zhang, Y | 1 |
| Diao, L; Fan, Y; Giri, U; Gudikote, J; Herbst, R; Heymach, JV; Johnson, BE; Koo, A; Lu, W; Nilsson, MB; Rowe, P; Ryan, A; Tang, X; Tong, P; Tran, H; Wang, J; Webster, A; Wistuba, II | 1 |
| Hadoux, J; Pacini, F; Schlumberger, M; Tuttle, RM | 1 |
| Cho, H; Choi, S; Kim, ND; Kwak, Y; Sim, T; Yoon, H | 1 |
| Bièche, I; Bonin, F; Château-Joubert, S; de Plater, L; Dieras, V; El Botty, R; Hatem, R; Labiod, D; Marangoni, E; Servely, JL; Vacher, S | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| De Andrade, JP; Gu, VW; Kulak, MV; Lorenzen, AW; Park, JM; Spanheimer, PM; Van Dorin, SE; Weigel, RJ; Woodfield, GW; Wu, VT | 1 |
| Bowler, KA; Burns, EM; Chapman, PJ; Fairweather, EE; Fritzl, SJR; Goldberg, KM; Hamilton, NM; Holt, SV; Hopkins, GV; Jones, SD; Jordan, AM; Lyons, AJ; Maguire, LA; McDonald, NQ; Mould, DP; Newton, R; Nikki March, H; Ogilvie, DJ; Purkiss, AG; Small, HF; Stowell, AIJ; Thomson, GJ; Waddell, ID; Waszkowycz, B; Watson, AJ | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ | 1 |
| Barbry, P; Belléannée, G; Blanck, O; Bonnetaud, C; Bordone, O; Bozec, A; Brest, P; Butori, C; Catargi, B; Guevara, N; Hénaoui, IS; Hofman, P; Hofman, V; Ilie, M; Lassalle, S; Lemaire, G; Long, E; Mari, B; Patey, M; Peyrottes, I; Popa, A; Sadoul, JL; Santini, J; Tissier, F; Trouette, H; Vielh, P; Zangari, J | 1 |
| Choi, YL; Han, J; I, H; Kim, J; Kim, RN; Kim, YD; Kim, YJ; Lee, CH; Lee, MK; Lee, MS; Lira, ME; Mao, M; Noh, KW; Oh, DY; Song, JY; Yang, JW | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| Ali, SM; Busaidy, NL; Chmielecki, J; Elvin, JA; Erlich, RL; Heilmann, AM; Khan, SA; Lipson, D; Miller, VA; Murthy, R; Nangia, C; Ross, JS; Shah, MH; Sherman, SI; Stephens, PJ; Subbiah, I; Subbiah, V; Sun, JX; Vergilio, JA; Wang, K; Yelensky, R | 1 |
| Bird, BH; Dodd, KA; Erickson, BR; Shrivastava-Ranjan, P; Spiropoulou, CF | 1 |
| Badziong, J; Führer, D; Herold, T; Schmid, KW; Tiedje, V; Ting, S; Walter, RF; Worm, K; Zwanziger, D | 1 |
| Learoyd, DL; Robinson, BG; Tsang, VH | 1 |
| Chabre, O; Dupuis, C; Durand, C; Piolat, C; Plantaz, D; Segura, D | 1 |
| Li, J; Liu, Z; Lu, D; Wang, H; Wang, J; Wei, X; Xie, H; Xu, X; Zheng, S; Zhuang, R | 1 |
| Chen, D; Coffman, TM; Jensen, BL; Johnsen, I; Madsen, K; Tinning, AR | 1 |
| Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takata, S; Takigawa, N; Tanimoto, M | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Chen, Y; Dong, Y; Jiang, Z; Li, Y; Pei, H; Peng, Y; Shao, T; Sun, Z; Tang, W; Wang, J; Yi, Z; Zhou, W | 1 |
| Antonelli, A; Baldini, E; Biricotti, M; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Ulisse, S | 1 |
| Chen, AY; Ernani, V; Kumar, M; Owonikoko, TK | 1 |
| Collins, L; Corner, C; Goff, M; Gupta, A; Kelly, C; Lester, J; Love, S; Marshall, E; Middleton, MR; Nobes, J; Roberts, C; Salisbury, A; Tysoe, F; Wise, A; Wolstenholme, V; Woodward, M | 1 |
| Matsuhashi, N; Matsui, S; Okumura, N; Osada, S; Sasaki, Y; Takahashi, T; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yawata, K; Yoshida, K | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Lee, JK; Lee, SH; Min, HS; Park, K; Sun, JM | 1 |
| Horiuchi, K; Ito, Y; Komoda, M; Okamoto, T; Rito, K; Takahashi, S; Todo, T; Tomomatsu, J; Tsuji, A; Uchino, K | 1 |
| Goto, K; Ishii, G; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Ohe, Y; Ohtsu, A; Sato, A; Satouchi, M; Seto, T; Tsuchihara, K; Tsuta, K; Yamamoto, N; Yoh, K | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Alifano, M; Bienvenu-Perrard, M; Bricaire, L; Burnichon, N; Cochand-Priollet, B; Groussin, L; Lahlou, N; Louiset, E; Paepegaey, AC; Sarfati, PO | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Czuczman, P; Hagan, A; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Cohen, PR; Udkoff, J | 1 |
| Edwards, A; Glass, JO; Li, Y; Patay, Z; Reddick, WE; Svolos, P; Sykes, A | 1 |
| Hong, SK; Park, JI; Starenki, D; Wu, PK | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Accardo, G; Avenia, N; Castaldo, F; Colantuoni, V; Conzo, G; Di Donna, C; Esposito, D; Gambardella, C; Giugliano, D; Mazzella, M; Pasquali, D; Polistena, A | 1 |
| Alsaid, MS; Ghorab, MM; Ragab, FA; Soliman, AM | 1 |
| Hedayati, M; Rajabi, S | 1 |
| Fisher, PB; Konar, S; Kumar, BNP; Mandal, M; Pathak, A; Prasad, PN; Rajput, S; Rao, RR; Sarkar, S | 1 |
| Bengoetxea, H; Bulnes, S; Lafuente, JV; Requejo, C; Ruiz-Ortega, JA; Ugedo, L | 1 |
| Alias, Z; Ghani, H; Hamzah, NAB; Kabir, MZ; Mohamad, SB; Tayyab, S | 1 |
| Chen, X; He, Q; Li, H; Li, M; Liu, Y; Long, Y; Lu, L; Qiu, Y; Tang, J; Wang, X; Yu, Q; Zhang, Z | 1 |
| Hadoux, J; Schlumberger, M | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Hou, S; Li, Y; Liu, Q; Liu, Y; Qi, M; Shao, L; Zhang, J | 1 |
| Broniscer, A; Merchant, TE; Nguyen, R; Onar-Thomas, A; Patay, Z; Pierson, CR | 1 |
| Akshintala, S; Balis, FM; Derse-Anthony, C; Dombi, E; Fox, E; Glod, JW; Kapustina, O; Kraft, IL; Lei, H; Lodish, M; Meltzer, PS; Merino, MJ; Shern, JF; Steinberg, SM; Waguespack, SG; Widemann, BC; Zhu, Y | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Araki, M; Chauhan, R; Goto, K; Ichikawa, H; Ishii, G; Knowles, PP; Kohno, T; Matsumoto, S; McDonald, NQ; Mimaki, S; Nagatoishi, S; Nakaoku, T; Niho, S; Okuno, Y; Shimada, Y; Tsuchihara, K; Tsumoto, K; Yoh, K | 1 |
| Li, C; Wei, G; Yang, C | 1 |
| Droeser, R; Kouraklis, G; Patsouris, E; Tampaki, EC; Tampakis, A | 1 |
| Baple, EL; Brooke, A; Derse-Anthony, C; Glod, J; Newbold, K; Osborne, N; Sturley, R; Thomas, N; Vaidya, B | 1 |
| Antonelli, A; Baldini, E; Bocci, G; Di Desidero, T; Elia, G; Fallahi, P; Ferrari, SM; Fioravanti, A; La Motta, C; Materazzi, G; Miccoli, P; Orlandi, P; Paparo, SR; Patrizio, A; Piaggi, S; Ragusa, F; Ruffilli, I; Ulisse, S | 1 |
| Arriola-Villalobos, P; Benítez-Del-Castillo, JM; Benito-Pascual, B; Díaz-Valle, D | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Byun, B; Chae, JH; Hyun, SA; Kim, KS; Lee, HA | 1 |
| Cáncela-Díez, B; Cuenca-Barrales, C; Galvez-Moreno, M; López-Delgado, D; Ruiz-Villaverde, R | 1 |
| Das, SK; Emdad, L; Fisher, PB; Kumar, BNP; Kundu, SC; Mahto, MK; Mandal, M; Pathak, A; Puvvada, N; Rajput, S; Reis, RL; Sarkar, S; Yallapu, MM | 1 |
| Guo, J; Guo, T; Liu, D; Sun, Y; Wang, N; Zhu, X | 1 |
| Borchmann, S; Büttner, R; Dietlein, F; Florin, A; Golfmann, K; Hallek, M; Koker, M; Malchers, F; Meder, L; Rodrik-Outmezguine, V; Rosen, N; Tharun, L; Ullrich, RT; Volz, C | 1 |
| Bumrah, C; Cote, GJ; Giordano, TJ; Knippler, CM; Miles, W; Ringel, MD; Saji, M; Valenciaga, A; Yilmaz, AS; Yu, L; Zhang, X | 1 |
| Balasubramaniam, S; Del Rivero, J; Edgerly, M; Fojo, T; Gramza, AW; Madan, RA; Ward, J | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| MacGregor, FB; Milner, TD; Reed, N; Ronghe, M; Shaikh, MG | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Dagogo-Jack, I; Ferris, L; Gainor, JF; Lin, JJ; Nagy, R; Shaw, AT; Stevens, SE | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Colombo, C; De Leo, S; Di Stefano, M; Fugazzola, L; Persani, L; Vannucchi, G | 1 |
| Ali, SM; Chung, JH; DiClemente, F; Dolfi, SC; Ganesan, S; Gay, LM; Hirshfield, KM; Kulkarni, A; Lee, E; Leyland-Jones, B; Lin, S; Liu, C; Paratala, BS; Petrosky, W; Pham, K; Rodriguez-Rodriguez, L; Ross, JS; Schrock, AB; Williams, CB; Williams, K; Yao, M; Yilmazel, B | 1 |
| Dedecjus, M; Druce, M; Elisei, R; Gagel, RF; Hu, MI; Kapiteijn, E; Krajewska, J; Locati, L; Pacini, F; Popovtzer, A; Weiss, R | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Ferrari, M; Gu, J; Hamilton, DJ; Jiang, S; Li, F; Li, Z; Pettigrew, RI; Qiu, Y; Yang, Z | 1 |
| Al-Shakliah, NS; Bakheit, AH; Darwish, HW; Darwish, IA | 1 |
| Benhuri, B; Chaudhari, SP; Ciccolini, KT; Duran, J; Kim, J; Lacouture, ME; Lucas, AS; Wu, S | 1 |
| Balasubramanian, S; Carroll, C; Hamilton, J; Kaltenthaler, E; Moss, L; Tappenden, P; Wadsley, J; Wong, R | 1 |
| Adam, V; Arlt, VM; Heger, Z; Indra, R; Kolarik, M; Kopeckova, K; Stiborova, M | 1 |
| Britt, CJ; Russell, JO | 1 |
| Cai, J; Hilberg, F; Huang, Q; Liu, X; Mooers, BHM; Shen, T; Teng, P; Terzyan, SS; Wu, J; Zhou, M | 1 |
| Bascal, Z; Caine, M; Czuczman, P; Garcia, P; Hagan, A; Kilpatrick, H; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, G; Press, C; Tang, Y | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Doan, HQ; Goldstein, J; Hu, MI; Patel, AB; Piha-Paul, SA; Subbiah, V | 1 |
| Brocato, RL; Hooper, JW | 1 |
| Chu, PL; Chua, KLM; Chua, MLK; Liang, ZG; Low, KP; Nei, WL; Poon, DJJ; Ramaswamy, B; Shihabuddeen, WA; Soo, KC; Thong, PSP; Yeo, ELL | 1 |
| Qiu, XY; Yin, Y; Zhang, B; Zhang, YH | 1 |
| Arnaldez, FI; Derdak, J; Derse-Anthony, C; Dombi, E; Glod, J; Helman, L; Killian, JK; Linehan, WM; Meltzer, P; Miettinen, M; Spencer, M; Srinivasan, R; Steinberg, SM; Widemann, BC; Wiener, L | 1 |
| Esmaeili, S; Fassihi, A; Fayyazi, N; Ghasemi, JB; Saghaie, L; Taheri, S | 1 |
| Kim, KW; Van den Abbeele, AD | 1 |
| Agate, L; Bottici, V; Cappagli, V; Ciampi, R; Elisei, R; Matrone, A; Molinaro, E; Piaggi, P; Ramone, T; Romei, C; Tacito, A; Valerio, L; Viola, D | 1 |
| Arulananda, S; John, T; Loh, Z; Mitchell, P | 1 |
| Adam, V; Arlt, VM; Eckschlager, T; Heger, Z; Indra, R; Jáklová, K; Kopečková, K; Pompach, P; Stiborová, M; Vavrová, K | 1 |
| Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM | 1 |
| Dai, Y; Geng, X; Gong, J; Liu, D; Ma, Z; Meng, H; Song, G; Song, Z; Yang, T; Zhou, B | 1 |
| Ahn, JS; Ahn, MJ; Ku, BM; La Choi, Y; Lee, J; Lee, SH; Park, K; Shim, JH; Sun, JM | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Herbaut-Barres, B; Maret, D; Sibaud, V; Vigarios, E; Zerdoud, S | 1 |
| Su, Z; Tang, J; Wang, H | 1 |
| Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J | 1 |
| Bastholt, L; Colzani, R; Elisei, R; Foster, M; Haddad, R; Hauch, O; Jarząb, B; Kreissl, MC; Robinson, B; Schlumberger, M; Weiss, R | 1 |
| Barros Freiria, X; Calabia Martínez, J; Castillo Devia, M; García Méndez, I; Martin Alemany, N; Merino Ribas, A; Noboa Paez, C; Pérez Bueno, F; Pilco Teran, M; Rubio Casadevall, J; Torguet Escuder, P | 1 |
| Baudin, E; Berdelou, A; Borget, I; Hecht, F; Leboulleux, S; Ramos, HE; Schlumberger, M | 1 |
| Balcı, Y; Çağlar Çıtak, E; Demir Gündoğan, B; Sağcan, F; Tuğ Bozdoğan, S; Tuncel Daloğlu, F | 1 |
| Akagunduz, B; Çoban, A; Guven, DC; Kara, AV; Mammadov, R; Ozcicek, F; Suleyman, B; Suleyman, H; Yazici, GN | 1 |
| Kaushik, AC; Wang, X; Wang, YJ; Wei, DQ | 1 |
| Adam, P; Allelein, S; Berg, E; Frank-Raue, K; Hoster, E; Koehler, VF; Kroiss, M; Raue, F; Schott, M; Spitzweg, C | 1 |
| Kitamura, S; Maeda, T; Yanagi, T | 1 |
| Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A | 1 |
| Ahn, J; Jeon, MJ; Kang, HC; Kim, BH; Kim, HK; Kim, IJ; Kim, M; Kim, TY; Lim, DJ; Shong, YK; Yoon, JH | 1 |
| Ahn, HY; Chae, JE; Kim, SG; Moon, H; Noh, J; Park, YJ | 1 |
| Inui, KI; Masuda, S; Tanihara, Y | 1 |
| Adam, V; Heger, Z; Michalkova, H; Pribyl, J; Rex, S; Skladal, P; Skubalova, Z; Sukupova, M; Weerasekera, A; Zahalka, M | 1 |
| Amini, B; Bhatt, T; Cascone, T; Conley, AP; Drobnitzky, N; Falchook, GS; Fu, S; Hess, KR; Heymach, JV; Hong, DS; Janku, F; Karp, D; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Ryan, AJ; Sacks, RL; Sherman, SI; Subbiah, IM; Subbiah, V | 1 |
| Goto, K; Ikeno, T; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Nosaki, K; Sato, A; Satouchi, M; Seto, T; Tsuta, K; Wakabayashi, M; Yamamoto, N; Yoh, K | 1 |
| Borghi, MO; Cantone, MC; Carra, S; Dicitore, A; Gaudenzi, G; Ghilardi, A; Hofland, LJ; Persani, L; Plebani, A; Saronni, D; Vitale, G | 1 |
| Eckschlager, T; Feglarová, T; Heger, Z; Hodek, P; Hraběta, J; Indra, R; Jáklová, K; Kolárik, M; Rex, S | 1 |
| Carter, R; Hagan, AE; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ; Sharma, RA; Westhorpe, A; Znati, SA | 1 |
| Abdelhameed, AS; Al-Shakliah, NS; Alanazi, AM; AlRabiah, H; Attwa, MW; Hassan, ES | 1 |
| Bashir, A; Beck, AC; Erdahl, LM; Karwal, MW; Liao, J; Lizarraga, IM; Lorenzen, AW; Spanheimer, PM; Sugg, SL; Weigel, RJ | 1 |
| Abdelhameed, AS; Alanazi, AM; AlRabiah, H; Alruqi, OS; Attia, MI; Attwa, MW | 1 |
| Álvarez-Escolá, C; Castelo-Fernández, B; García-Moreno, RM; Moreno-Domínguez, Ó; Torres-Sánchez, I; Yébenes-Gregorio, L | 1 |
| Courtier, B; Hadoux, J | 1 |
| Jiang, D; Liu, J; Liu, X; Pan, Y; Qiu, Y; Shi, Y; Wan, H; Wang, P; Ying, K; Zhu, Y | 1 |
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Shen, X; Xu, Z; Yan, H; Yang, B | 1 |
| Brandenburg, T; Dralle, H; Führer, D; Muchalla, P; Schmid, KW; Theurer, S; Tiedje, V; Weber, F | 1 |
| Koehler, VF; Kroiss, M; Spitzweg, C | 1 |
| Hou, W; Li, S; Liao, H; Qiu, W; Yin, L; Zhan, J; Zhang, J | 1 |
| Atkinson, D; Bandula, S; Bascal, ZA; Beaton, L; Boucher, E; Chouhan, M; Clarkson, MJ; Cooper, S; Counsell, N; Czuczman, P; Davidson, BR; Forsyth, S; Hague, J; Hartley, JA; Jansen, M; Lewis, AL; Lowe, HL; Meyer, T; Munneke, G; Pollok, JM; Raja, J; Ryan, S; Sharma, D; Sharma, RA; Stuckey, DJ; Thin, MZ; Tregidgo, HFJ; Wilde, PE; Znati, SA | 1 |
| Cui, X; Li, C; Ma, J; Qiu, S; Shi, C; Sun, J; Xu, Y | 1 |
| Dai, B; Du, X; Gong, Z; Ji, Y; Li, S; Ma, W; Shi, X; Wang, B; Wang, Y; Yang, T; Zhan, Y; Zhang, D; Zhang, Y; Zhu, M | 1 |
| Bardet, S; Brose, MS; Capdevila, J; Elisei, R; Führer, D; Gao, M; Hadoux, J; Hoff, AO; Hu, MI; Isaev, P; Jarzab, B; Keam, B; Kopeckova, K; Lin, B; Lin, Y; Maeda, P; Robinson, BG; Sherman, EJ; Singh, R; Soldatenkova, V; Tahara, M; Wadsley, J; Wirth, LJ; Wright, J | 1 |
115 review(s) available for quinazolines and zd 6474
| Article | Year |
|---|---|
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
ZD-6474. AstraZeneca.
Topics: Animals; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Piperidines; Quinazolines; Technology, Pharmaceutical | 2003 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
ZD6474--clinical experience to date.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Topics: Administration, Oral; Biological Availability; Cell Survival; Drug Administration Schedule; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Antiangiogenic drugs in non-small cell lung cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neovascularization, Pathologic; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Molecular Structure; Neoplasms; Piperidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Drug insight: VEGF as a therapeutic target for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2007 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2010 |
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.
Topics: Animals; Apoptosis; Carcinoma; Chemotherapy, Adjuvant; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Antiangiogenic therapies for malignant pleural mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Humans; Mesothelioma; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pleural Effusion, Malignant; Pleural Neoplasms; Quinazolines; Quinolines; Thoracic Cavity; Vascular Endothelial Growth Factors | 2011 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Vandetanib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2011 |
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Vandetanib (Caprelsa) for medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Drug Costs; Drug Interactions; Humans; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2012 |
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Female; Humans; Male; Molecular Targeted Therapy; Mutation; Piperidines; Prognosis; Quinazolines; Signal Transduction; Thyroid Neoplasms; Time Factors; TOR Serine-Threonine Kinases | 2012 |
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Electrocardiography; Humans; Incidence; Middle Aged; Neoplasms; Odds Ratio; Piperidines; Quinazolines; Risk Factors | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Management of thyroid carcinoma in children and young adults.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Iodine Isotopes; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Thyrotropin; Young Adult | 2012 |
Kinase inhibitors for advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Patient Selection; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
Vandetanib for the treatment of lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Vandetanib: in medullary thyroid cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Metastasis; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Hypertension; Incidence; Neoplasms; Piperidines; Publication Bias; Quinazolines; Risk | 2013 |
Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Vandetanib therapy in medullary thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Interactions; ErbB Receptors; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2012 |
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2013 |
Vandetanib and the management of advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib for the treatment of medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Drugs, Investigational; Humans; Medical Oncology; Piperidines; Professional Practice; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Fees, Pharmaceutical; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2013 |
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Bibliographic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
A Drosophila approach to thyroid cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Interactions; Drug Labeling; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2014 |
The discovery and development of vandetanib for the treatment of thyroid cancer.
Topics: Disease-Free Survival; Drug Discovery; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of thyroid cancer: an update.
Topics: Animals; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Epidermal Growth Factor; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Vandetanib as a potential treatment for breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rare Diseases; Thyroid Neoplasms | 2014 |
Novel therapies for thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Clinical Trials as Topic; Diarrhea; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Long QT Syndrome; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Topics: Anilides; Antineoplastic Agents; Drug Monitoring; Evidence-Based Medicine; Humans; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Selective use of vandetanib in the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thyroid Neoplasms; Treatment Outcome | 2015 |
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
Topics: Antineoplastic Agents; Drug Monitoring; Gastrointestinal Diseases; Humans; Incidence; Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Management of advanced medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Biomarkers; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
The safety of vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Disease Progression; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
Systemic treatment and management approaches for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Genotype; Humans; Molecular Targeted Therapy; Phenotype; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptors, Fibroblast Growth Factor; Thyroid Neoplasms; Thyroidectomy; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Genetics of medullary thyroid cancer: An overview.
Topics: Anilides; Carcinoma, Medullary; Codon; Exons; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Mutation; Piperidines; Polymorphism, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; High-Throughput Nucleotide Sequencing; Humans; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Exanthema; Humans; Incidence; Inflammatory Breast Neoplasms; Neoplasm Staging; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2017 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Incidence and risk of developing photosensitivity with targeted anticancer therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Clinical Trials as Topic; Humans; Incidence; Molecular Targeted Therapy; Neoplasms; Nivolumab; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Vemurafenib | 2019 |
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cost-Benefit Analysis; England; Humans; Models, Economic; Piperidines; Pyridines; Quality-Adjusted Life Years; Quinazolines; Technology Assessment, Biomedical; Thyroid Neoplasms | 2019 |
Vandetanib photoinduced cutaneous toxicities.
Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Drug Eruptions; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2019 |
Progress on the Prevention and Treatment of Hantavirus Disease.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines | 2019 |
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Topics: Acute Disease; Adult; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Follow-Up Studies; France; Humans; Pancreatitis; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2020 |
88 trial(s) available for quinazolines and zd 6474
| Article | Year |
|---|---|
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Piperidines; Quinazolines; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2005 |
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Topics: Administration, Oral; ErbB Receptors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2006 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Thoracic Neoplasms; Treatment Outcome | 2006 |
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quinazolines; Taxoids | 2007 |
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Topics: Adult; Aged; Carcinoma, Small Cell; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quality of Life; Quinazolines; Treatment Outcome | 2007 |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Treatment Outcome | 2009 |
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Quinazolines | 2009 |
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Piperidines; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2009 |
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytokines; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Disease-Free Survival; Drug Administration Schedule; Female; France; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pedigree; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Recurrence; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Codon; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Young Adult | 2010 |
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Europe; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Patient Selection; Piperidines; Placebos; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; South Africa; Taiwan; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Piperidines; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Contrast Media; Epidermal Growth Factor; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Piperidines; Quinazolines; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Mexico; Middle Aged; Pemetrexed; Piperidines; Proportional Hazards Models; Quinazolines; Risk Assessment; Risk Factors; South Africa; Time Factors; Treatment Outcome | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Humans; Itraconazole; Male; Piperidines; Quinazolines; Rifampin | 2011 |
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Middle Aged; Neovascularization, Pathologic; Nitric Oxide; Piperidines; Prospective Studies; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Cells, Cultured; Vasodilation | 2011 |
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Piperidines; Quinazolines; Young Adult | 2011 |
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Blood Glucose; Calcium; Cross-Over Studies; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Testosterone; Thyroid Neoplasms; Treatment Outcome; Vitamin D | 2011 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Topics: Carcinoma, Neuroendocrine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Placebos; Quinazolines; Thyroid Neoplasms | 2012 |
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium | 2012 |
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Double-Blind Method; Feces; Female; Food-Drug Interactions; Half-Life; Humans; Male; Metabolic Clearance Rate; Metabolomics; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Quinazolines; United Kingdom; Young Adult | 2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; ErbB Receptors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2012 |
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Smoking; Treatment Outcome | 2012 |
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Drug Approval; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; United States; United States Food and Drug Administration | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Platelet Factor 4; Proteomics; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Young Adult | 2012 |
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Female; Folliculitis; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Blood Volume; Brain Stem Neoplasms; Child; Child, Preschool; Cohort Studies; Disease Progression; Echo-Planar Imaging; Female; Follow-Up Studies; Glioma; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neuroimaging; Piperidines; Prospective Studies; Quinazolines; Radiotherapy, Conformal; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2013 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Topics: Adult; Aged; Body Composition; Carcinoma, Neuroendocrine; Cross-Over Studies; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2013 |
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Topics: Acute-Phase Proteins; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Amplification; Genes, erbB-1; Humans; Interleukin-9; Kaplan-Meier Estimate; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids | 2013 |
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2013 |
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Platinum Compounds; Quinazolines; Vascular Endothelial Growth Factor A | 2013 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2013 |
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheters, Indwelling; Humans; Lung Neoplasms; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pleurodesis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recurrence; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Piperidines; Postmenopause; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; Male; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2014 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2016 |
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Sirolimus | 2015 |
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2015 |
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Prevalence; Proto-Oncogene Proteins c-ret; Quinazolines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dermatitis, Photoallergic; Everolimus; Female; Humans; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Piperidines; Quinazolines; Temozolomide; Treatment Outcome | 2015 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome | 2017 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Piperidines; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy | 2016 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome; Tumor Burden | 2017 |
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2017 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Order; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2017 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.
Topics: Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dexamethasone; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Piperidines; Prospective Studies; Quinazolines; Steroids; Vascular Endothelial Growth Factor A; White Matter | 2017 |
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Glioma; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Male; Piperidines; Quinazolines; Radiotherapy, Conformal; Stroke; Tumor Burden | 2017 |
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Topics: Antineoplastic Agents; Bortezomib; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2019 |
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Young Adult | 2019 |
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
Topics: Adolescent; Adult; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins c-kit; Quality of Life; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Young Adult | 2019 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Neoplasms; Piperidines; Proto-Oncogene Mas; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2021 |
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Ki-67 Antigen; Middle Aged; Pilot Projects; Piperidines; Preoperative Care; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2021 |
Phase 3 Trial of Selpercatinib in Advanced
Topics: Antineoplastic Agents; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2023 |
337 other study(ies) available for quinazolines and zd 6474
| Article | Year |
|---|---|
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biological Availability; Cell Division; Cells, Cultured; Dogs; Endothelium, Vascular; Enzyme Inhibitors; Humans; Male; Mice; Mice, Nude; Piperidines; Proto-Oncogene Proteins; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1 | 2002 |
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Endothelial Growth Factors; Enzyme Inhibitors; Female; Humans; Lymphokines; Male; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2002 |
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Topics: 3T3 Cells; Animals; Carcinoma, Papillary; Cell Transformation, Neoplastic; Drosophila Proteins; Enzyme Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Humans; Inhibitory Concentration 50; Neoplasms; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Topics: Agar; Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Hormonal regulation and functional role of vascular endothelial growth factor a in the rat testis.
Topics: Animals; Capillary Permeability; Chorionic Gonadotropin; Male; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Testis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Topics: Adenocarcinoma; Animals; Capillary Permeability; Contrast Media; Dose-Response Relationship, Drug; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms, Experimental; Piperidines; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2003 |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Topics: Adenocarcinoma; Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Membrane; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperidines; Precipitin Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2004 |
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Base Sequence; Carcinoma in Situ; DNA Primers; Female; Humans; Hyperplasia; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cysteine Endopeptidases; Enzyme Inhibitors; Gene Rearrangement; Humans; MAP Kinase Signaling System; Multienzyme Complexes; Oncogene Proteins, Fusion; Piperidines; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2004 |
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Topics: Carcinoma, Medullary; Catalytic Domain; Cell Line; Drug Resistance; Enzyme Inhibitors; Mitogens; Piperidines; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Valine | 2004 |
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Glioma; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Rats | 2004 |
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Capillaries; Cell Proliferation; Endothelial Cells; ErbB Receptors; Humans; Mice; Neovascularization, Pathologic; Pericytes; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Stomach Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Line, Transformed; Disease Models, Animal; Female; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines | 2004 |
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines; Sarcoma, Kaposi | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Topics: Base Sequence; Cell Line, Tumor; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Sequence Data; Neoplasms; Piperidines; Quinazolines; Transfection; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Endothelial Cells; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Piperidines; Quinazolines; Radiotherapy; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Castration; Cell Division; Combined Modality Therapy; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Orchiectomy; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Topics: Carcinoma, Medullary; Carcinoma, Papillary; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Mutation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Thyroid Neoplasms; Treatment Outcome | 2004 |
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Pyrazoles; Quinazolines; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Flow Cytometry; Immunohistochemistry; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neovascularization, Pathologic; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Quinazolines; Stem Cells; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Topics: Animals; Carcinoma, Papillary; Disease Models, Animal; Drosophila; Drosophila Proteins; ErbB Receptors; Eye Abnormalities; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Isoforms; Proto-Oncogene Proteins c-ret; Quinazolines; raf Kinases; ras Proteins; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms | 2005 |
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Topics: Animals; Blood Vessels; Carcinoma, Renal Cell; Cell Division; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines | 2004 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Topics: Acetates; Animals; Antineoplastic Agents; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, Liquid; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Ions; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Pentanes; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tissue Distribution; Trazodone | 2005 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Collagen; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Glioblastoma; Humans; Immunohistochemistry; In Vitro Techniques; Laminin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Proteoglycans; Quinazolines; Radiation, Ionizing; Time Factors; Vascular Endothelial Growth Factor A | 2005 |
The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
Topics: Animals; Body Weight; Dermatologic Surgical Procedures; Female; Mice; Mice, Inbred BALB C; Microcirculation; Neovascularization, Physiologic; Piperidines; Quinazolines; Signal Transduction; Skin; Stress, Mechanical; Vascular Endothelial Growth Factor Receptor-2; Wound Healing; Wounds and Injuries | 2005 |
Molecule-kinase interaction map.
Topics: Animals; Computational Biology; Drug Design; ErbB Receptors; Genetic Variation; Humans; Microchemistry; Mutation; Pharmaceutical Preparations; Piperidines; Programming Languages; Protein Interaction Mapping; Quinazolines; Software; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Ependymoma; ErbB Receptors; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Adhesion Molecules; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Matrix Proteins; Humans; Immunoprecipitation; Inhibitory Concentration 50; Kalinin; Liver Neoplasms; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2006 |
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocyte Depletion; Mice; Mice, SCID; Neovascularization, Pathologic; Piperidines; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2005 |
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
ZD6474 headed for phase III trials in the fall.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Piperidines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Spodoptera; Thyroid Neoplasms | 2006 |
Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Area Under Curve; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Estradiol; Feces; Female; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tissue Distribution; Transplantation, Heterologous | 2006 |
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2006 |
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Female; HT29 Cells; Humans; Mice; Mice, Inbred Strains; Mice, Nude; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; G2 Phase; Humans; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Two targets, one drug for new EGFR inhibitors.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lapatinib; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor | 2006 |
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Piperidines; Quinazolines; Signal Transduction; Time Factors | 2006 |
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoproteins; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous | 2006 |
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma; Castration; Combined Modality Therapy; Dose-Response Relationship, Drug; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2006 |
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines | 2007 |
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; ErbB Receptors; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Drug Synergism; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Piperidines; Quinazolines; Tumor Cells, Cultured | 2007 |
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Angiogenic inhibition reduces germinal matrix hemorrhage.
Topics: Aborted Fetus; Angiopoietin-2; Animals; Blotting, Western; Brain; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Endothelial Cells; Humans; Immunohistochemistry; Infant, Newborn; Infant, Premature; Intracranial Hemorrhages; Neovascularization, Physiologic; Piperidines; Pyrazoles; Quinazolines; Rabbits; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Topics: Animals; Calibration; Cell Proliferation; Colonic Neoplasms; Contrast Media; Disease Models, Animal; Heart Ventricles; Hemodynamics; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Organometallic Compounds; Piperidines; Quinazolines; Rats; Rats, Nude | 2008 |
Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
Topics: Adenosine Triphosphate; Amides; Azoles; Binding, Competitive; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Chemical; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Topics: Aged; Animals; Calcitonin; Carcinoma, Medullary; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromogranin A; Disease Models, Animal; ErbB Receptors; Humans; Karyotyping; Male; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.
Topics: Animals; Antibodies; Cell Line; Endothelial Cells; Gene Expression Regulation; Health; Humans; Hypertension; Kidney; Kidney Function Tests; Male; Microscopy, Electron, Transmission; Phosphorylation; Piperidines; Quinazolines; Rats; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pleural Effusion; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
Topics: Adenosine Triphosphatases; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Piperidines; Quinazolines; Rhodamine 123; Tumor Cells, Cultured | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
Paucity of pericytes in germinal matrix vasculature of premature infants.
Topics: Animals; Antigens; Antigens, CD34; Autopsy; Blood-Brain Barrier; Cadherins; Cerebral Cortex; Female; Fetus; Gestational Age; Humans; Infant, Newborn; Lysophospholipids; Pericytes; Piperidines; Pregnancy; Premature Birth; Proteoglycans; Quinazolines; Rabbits; Sphingosine; Time Factors; Transforming Growth Factor beta1 | 2007 |
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Piperidines; Quinazolines | 2007 |
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Dextrans; Ferrosoferric Oxide; Gadolinium DTPA; Glioma; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Oxides; Piperidines; Predictive Value of Tests; Quinazolines; Transplantation, Heterologous | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; Piperidines; Quinazolines; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Drug Delivery Systems; Endothelium; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
EGFR and VEGFR as potential target for biological therapies in HCC cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2008 |
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.
Topics: Administration, Oral; Animals; Combinatorial Chemistry Techniques; Inhibitory Concentration 50; Ketones; Mice; Molecular Structure; Piperidines; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Topics: Animals; Base Sequence; Cell Line, Tumor; DNA Primers; Lymphatic Metastasis; Mice; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunoprecipitation; Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Topics: Animals; Apoptosis; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Necrosis; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Parotid Neoplasms; Phosphorylation; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Muscle Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2008 |
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Docetaxel; Endothelial Cells; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Piperidines; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Topics: Amino Acid Sequence; Drug Resistance, Neoplasm; HeLa Cells; Humans; Kidney; Molecular Sequence Data; Mutagenesis, Site-Directed; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Tyrosine | 2009 |
Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agent.
Topics: Chemistry, Pharmaceutical; Crystallization; Ethanol; Microspheres; Particle Size; Polyesters; Protein Kinase Inhibitors; Quinazolines; Solvents | 2009 |
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Topics: Administration, Oral; Animals; Biological Availability; Female; Isoquinolines; Mice; Mice, Inbred Strains; Phthalazines; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Piperidines; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2009 |
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.
Topics: Animals; Biological Transport; Carbon Radioisotopes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Microsomes; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radioactive Tracers; Radiochemistry; Rats; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Japan; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Multidrug Resistance-Associated Proteins; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Cell Cycle; DNA Primers; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunohistochemistry; K562 Cells; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Transplantation, Heterologous | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Meta-Analysis as Topic; Piperidines; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Polymerase Chain Reaction; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2009 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors | 2010 |
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; Cellulase; Corneal Diseases; Corneal Opacity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ointments; Piperidines; Quinazolines; Retrospective Studies; Sodium Chloride; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Topics: Animals; Carcinoma, Squamous Cell; Cell Movement; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Severe photosensitivity reaction to vandetanib.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2009 |
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Vorinostat | 2009 |
Lung cancer trials probe effects of maintenance therapy, targeted agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Female; Humans; Hyperpigmentation; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin | 2009 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.
Topics: Animals; Contrast Media; Electron Spin Resonance Spectroscopy; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Oxygen Consumption; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
Topics: Amino Acid Sequence; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; Carcinoma, Papillary; Cell Division; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Molecular Sequence Data; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyrrolidinones; Quinazolines; Rats; Thyroid Neoplasms; Type C Phospholipases | 2010 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?
Topics: Biomarkers, Tumor; Blood Chemical Analysis; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Predictive Value of Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2010 |
ZD6474 coerces breast cancer for an apoptotic journey.
Topics: Apoptosis; Breast Neoplasms; Female; Humans; Piperidines; Quinazolines | 2010 |
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Humans; Isotretinoin; Mice; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
[Inhibitory effect of ZD6474 combined with adriamycin on MCF-7 human breast cancer cells in vitro].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Female; Humans; Piperidines; Quinazolines | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Topics: Animals; bcl-X Protein; Brain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Magnetic Resonance Imaging; Mice; Mutant Proteins; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
One more fallen star--ZODIAC and its implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2010 |
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Paclitaxel; Piperidines; Quinazolines | 2011 |
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Piperidines; Quinazolines | 2010 |
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Humans; Mesoderm; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Urinary Bladder Neoplasms; Vimentin | 2010 |
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Topics: Adenoma; Animals; Antineoplastic Agents; beta Catenin; Colitis; Colonic Neoplasms; Dextran Sulfate; Disease Models, Animal; ErbB Receptors; Genes, APC; Intestine, Small; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Glioma; Multivariate Analysis; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proteomics; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors | 2010 |
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Image Enhancement; Kinetics; Male; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Nude; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2010 |
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Topics: Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Immunohistochemistry; Mice; Mice, Inbred CBA; Mouth Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor | 2010 |
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Topics: Antineoplastic Agents; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Piperidines; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia; Methotrexate; Piperidines; Protein Kinase Inhibitors; Quinazolines; Topoisomerase II Inhibitors | 2012 |
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Proteins; Piperidines; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Fibronectins; Humans; Mice; Mice, SCID; Piperidines; Quinazolines; Recombinant Fusion Proteins; Single-Chain Antibodies; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2011 |
New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; ErbB Receptors; Fibroblast Growth Factor 2; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Molecular Structure; Neovascularization, Physiologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor A | 2012 |
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Immunoblotting; In Situ Nick-End Labeling; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Metabolic imaging allows early prediction of response to vandetanib.
Topics: Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Dihydroxyphenylalanine; Down-Regulation; Female; Fluorodeoxyglucose F18; G1 Phase; Glucose; Humans; Male; Mice; Mice, SCID; Microarray Analysis; Piperidines; Positron-Emission Tomography; Proto-Oncogene Proteins c-ret; Quality Control; Quinazolines; Radiopharmaceuticals; Resting Phase, Cell Cycle; RNA, Neoplasm; Signal Transduction; Thymidine; Thyroid Neoplasms; Tomography, Emission-Computed | 2011 |
[Pleural metastases from bronchial carcinoma: is a cure possible?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pleural Neoplasms; Quinazolines; Radiotherapy; Receptor Protein-Tyrosine Kinases; Retreatment; Survivors; Thoracotomy | 2011 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Piperidines; Quinazolines; Tegafur; Tumor Cells, Cultured | 2011 |
Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Topics: Adult; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hyperpigmentation; Lasers, Solid-State; Piperidines; Protein Kinase Inhibitors; Quinazolines; Skin Pigmentation | 2011 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, SCID; Neoplasms; Phenotype; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Topics: Carbon Radioisotopes; Chlorine; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Methylation; Molecular Structure; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor | 2011 |
2011 ASCO Genitourinary Cancers Symposium.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Updates in the management of medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Contraindications; Humans; Multiple Endocrine Neoplasia; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Research; Syndrome; Thyroid Neoplasms | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Vandetanib: first global approval.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Approval; Drug Design; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemical Fractionation; Child; Chromatography, Liquid; Drug Stability; Humans; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dog Diseases; Dogs; Epidermal Growth Factor; ErbB Receptors; Female; Mammary Neoplasms, Animal; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Topics: Apoptosis; Blotting, Western; Carboplatin; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Pemetrexed; Phosphorylation; Piperidines; Pleural Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cornea; Corneal Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Microscopy, Acoustic; Piperidines; Quinazolines; Visual Acuity | 2011 |
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Injections, Intraperitoneal; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Diffuse interstitial lung disease linked to vandetanib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Hypersensitivity; Drug Substitution; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Spirometry; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Hep G2 Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunoprecipitation; In Vitro Techniques; Mice; Molecular Targeted Therapy; Piperidines; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2012 |
RET, ROS1 and ALK fusions in lung cancer.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytoskeletal Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; Piperidines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors | 2012 |
KIF5B-RET fusions in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Animals; Cell Transformation, Neoplastic; ErbB Receptors; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Japan; Kinesins; Lung Neoplasms; Mice; NIH 3T3 Cells; Norway; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; United States | 2012 |
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluoresceins; Fluorescent Dyes; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rhodamine 123; Time Factors | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Microvessels; Piperidines; Quinazolines; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Piperidines; Protein Binding; Quinazolines; Quinolines | 2012 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; Blood Vessels; Cell Hypoxia; Cell Line, Tumor; False Negative Reactions; Female; Humans; Magnetic Resonance Imaging; Male; Mammary Neoplasms, Experimental; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rats; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred Strains; Piperidines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Piperidines; Prognosis; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Dogs; Drug Synergism; Everolimus; Male; Mice; Piperidines; Quinazolines; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases | 2012 |
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.
Topics: Animals; Antioxidants; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Blotting, Western; Butylated Hydroxytoluene; Carcinogens; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hypoxia; Immunoenzyme Techniques; Lung Neoplasms; Methylcholanthrene; Mice; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-myc; Pulmonary Alveoli; Quinazolines; Sleep Apnea Syndromes; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
[The role of Src kinase inhibitor ZD6474 on multi-drug resistant K562/A02 cells].
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; K562 Cells; Mice; Mice, Inbred BALB C; Piperidines; Quinazolines; src-Family Kinases | 2012 |
Treating advanced radioresistant differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
First do no harm: counting the cost of chasing drug efficacy.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Hantavirus treatments advance amidst outbreak in US park.
Topics: Animals; California; Cricetinae; Disease Models, Animal; Disease Outbreaks; Hantavirus Pulmonary Syndrome; Humans; Mesocricetus; Orthohantavirus; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; United States; Viral Vaccines | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Vandetanib: too dangerous in medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Evidence-Based Medicine; Humans; Patient Safety; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thyroid Neoplasms; Treatment Outcome | 2012 |
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib | 2013 |
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.
Topics: Biopsy, Fine-Needle; Calcitonin; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Lymph Nodes; Lymphatic Diseases; Middle Aged; Neck; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Gland; Thyroid Neoplasms; Thyroid Nodule; Thyrotropin; Tomography, X-Ray Computed; Ultrasonography | 2013 |
Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Chromatography, Liquid; Doxorubicin; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry | 2013 |
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.
Topics: Adult; Carcinoma, Neuroendocrine; Cardiomyopathies; Clinical Trials, Phase III as Topic; Fatal Outcome; Female; Heart Failure; Humans; Male; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Cyclic N-Oxides; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Mitochondria; Nitrogen Oxides; Organophosphorus Compounds; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Down-Regulation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; RNA, Messenger; Signal Transduction; Transcriptome | 2013 |
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Glioblastoma; Humans; Male; Middle Aged; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2013 |
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Survival; Chloroquine; ErbB Receptors; Glioblastoma; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Isolation and structure elucidation of the main UV-A photoproducts of vandetanib.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Kinetics; Magnetic Resonance Spectroscopy; Mass Spectrometry; Photochemistry; Photolysis; Piperidines; Quinazolines; Solutions; Solvents; Ultraviolet Rays | 2013 |
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Topics: Adrenocorticotropic Hormone; Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Deamino Arginine Vasopressin; Humans; Lymphatic Metastasis; Male; Middle Aged; Paraneoplastic Syndromes; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2013 |
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Topics: Anilides; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2013 |
Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line; Cisplatin; Creatinine; HEK293 Cells; Humans; Kidney; Metformin; Organic Cation Transport Proteins; Piperidines; Quinazolines | 2013 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Hypertension; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Piperidines; Proteinuria; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Systole | 2013 |
Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2.
Topics: Angiogenesis Inhibitors; Animals; Binding Sites; Cell Line; Cell Survival; Dimerization; Female; Heterografts; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Molecular Imaging; Molecular Structure; Neoplasm Transplantation; Piperidines; Protein Binding; Quinazolines; Substrate Specificity; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; Cell Movement; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cytoskeleton; ErbB Receptors; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Membrane Potential, Mitochondrial; Molecular Targeted Therapy; Phototherapy; Piperidines; Quinazolines; Ultraviolet Rays; Ultraviolet Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Topics: Adult; Animals; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Signaling System; Mice; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thyroid Neoplasms | 2014 |
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Biological Assay; Biosensing Techniques; Breast Neoplasms; Cell Proliferation; Dielectric Spectroscopy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Equipment Design; Equipment Failure Analysis; Female; Humans; MCF-7 Cells; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2014 |
Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Down-Regulation; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Matrix Metalloproteinase 14; Neoplasm Invasiveness; Neuroblastoma; Phosphorylation; Piperidines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, CXCR4 | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.
Topics: Animals; Biosensing Techniques; Cell Line; Chitosan; Electrochemical Techniques; Endothelial Cells; Graphite; Immunoassay; Macaca mulatta; Niacinamide; Oxidation-Reduction; Phenothiazines; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retina; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2014 |
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
Topics: Adolescent; Adrenocorticotropic Hormone; Carcinoma, Neuroendocrine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cushing Syndrome; Humans; Male; Multiple Endocrine Neoplasia Type 2b; Neoplasms, Second Primary; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Dermatitis, Phototoxic; DNA Damage; Humans; Lysosomes; Mice; Mitochondria; Oxidation-Reduction; Piperidines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Bovine; Thiobarbituric Acid Reactive Substances; Ultraviolet Rays | 2014 |
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cyclic AMP Response Element-Binding Protein; Doxorubicin; Drug Synergism; Humans; MAP Kinase Signaling System; Mesothelioma; Mitogen-Activated Protein Kinase 7; Neoplasms, Connective Tissue; Phosphorylation; Piperidines; Quinazolines; RNA, Small Interfering; Sarcoma | 2014 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Topics: Adult; Alopecia Areata; Carcinoma, Neuroendocrine; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2015 |
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinogenesis; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Label-free single cell kinetics of the invasion of spheroidal colon cancer cells through 3D Matrigel.
Topics: Biosensing Techniques; Cell Culture Techniques; Cell Movement; Collagen; Colonic Neoplasms; Drug Combinations; Epidermal Growth Factor; HT29 Cells; Humans; Kinetics; Laminin; Microscopy; Piperidines; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Spheroids, Cellular | 2014 |
Photo-induced erythema multiforme associated with vandetanib administration.
Topics: Aged; Biopsy, Needle; Carcinoma, Medullary; Erythema Multiforme; Follow-Up Studies; Humans; Immunohistochemistry; Male; Neoplasm Staging; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Thyroid Neoplasms; Thyroidectomy | 2014 |
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Topics: Anilides; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Humans; Male; Middle Aged; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2014 |
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cytoskeletal Proteins; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2016 |
Endothelial progenitor cells induce transplant arteriosclerosis via VEGFR-1/2 activity.
Topics: Animals; Aorta; Arteriosclerosis; Bone Marrow Cells; Endothelial Cells; Flow Cytometry; Graft Rejection; Graft Survival; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphorylation; Piperidines; Quinazolines; Signal Transduction; Stem Cells; Transplantation, Homologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
Topics: Aged; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2015 |
DisABLing kidney cancers caused by fumarate hydratase mutations.
Topics: Animals; Fumarate Hydratase; Humans; Kidney Neoplasms; Oxidative Stress; Piperidines; Proto-Oncogene Proteins c-abl; Quinazolines | 2014 |
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.
Topics: Animals; Cell Line, Tumor; Cell Nucleus; Fumarate Hydratase; Fumarates; Gene Expression Regulation, Neoplastic; Glycolysis; HEK293 Cells; Humans; Kidney Neoplasms; Mice; Neoplasms, Experimental; NF-E2-Related Factor 2; Oxidative Stress; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-abl; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.
Topics: Cell Line, Tumor; Coculture Techniques; Human Umbilical Vein Endothelial Cells; Humans; Hydrogels; Intercellular Signaling Peptides and Proteins; Mechanotransduction, Cellular; Neoplasms; Neovascularization, Pathologic; Piperidines; Polyethylene Glycols; Quinazolines | 2015 |
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Female; France; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2015 |
Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes.
Topics: Action Potentials; Aged; Antineoplastic Agents; Electrocardiography, Ambulatory; Heart Conduction System; Heart Rate; Humans; Male; Piperidines; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Torsades de Pointes; Ventricular Fibrillation | 2015 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; rho GTP-Binding Proteins | 2015 |
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cytoskeletal Proteins; Drug Delivery Systems; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Essential; Humans; Lung Neoplasms; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; RNA; Sequence Analysis, RNA; Single-Cell Analysis; Transcriptome | 2015 |
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Topics: Adult; Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Quinazolines; Skin Diseases, Papulosquamous; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neuroimaging; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Piperidines; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni.
Topics: Animals; Antineoplastic Agents; Drug Repositioning; Inhibitory Concentration 50; Mice; Piperidines; Pyridones; Pyrimidinones; Quinazolines; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2015 |
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
Topics: Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Disease Progression; Female; Humans; Neoplasm Staging; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2015 |
Interaction of a tyrosine kinase inhibitor, vandetanib with human serum albumin as studied by fluorescence quenching and molecular docking.
Topics: Binding Sites; Circular Dichroism; Humans; Ligands; Metals; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Serum Albumin; Spectrometry, Fluorescence; Thermodynamics | 2016 |
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Piperidines; Quinazolines; Thyroid Neoplasms | 2016 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Piperidines; Quinazolines; Radiography; Transplantation, Heterologous | 2015 |
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Humans; Models, Molecular; Molecular Docking Simulation; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Thyroid Neoplasms | 2016 |
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Transcription Factor AP-2; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
Topics: Animals; Cell Line; Drug Design; Humans; Mice; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines | 2016 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Quinazolines; RNA Interference; Thyroid Neoplasms; Vesicular Transport Proteins | 2016 |
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Fusion; Piperidines; Protein Isoforms; Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Everolimus; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methionine; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; Threonine; Thyroid Neoplasms | 2016 |
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.
Topics: Animals; Capillary Permeability; Cricetinae; Disease Models, Animal; Endothelial Cells; Hantavirus Pulmonary Syndrome; Orthohantavirus; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Viral Load | 2016 |
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Mutation; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Topics: Carcinoma, Neuroendocrine; Child; Female; Humans; Lung Neoplasms; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2016 |
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Liver Neoplasms; Mice; Nanoparticles; Piperidines; Polymers; Quinazolines | 2016 |
Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney development.
Topics: Animals; Humans; Kidney; Mice; Mice, Knockout; Microvessels; Piperidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma; ErbB Receptors; Gene Expression Regulation; Hyperplasia; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colony-Forming Units Assay; Drug Design; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Stress Fibers; Thiazoles; Wound Healing | 2016 |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Female; Fluorouracil; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Stomach Neoplasms; Thymidylate Synthase; Tumor Burden | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Topics: Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Cytoreduction Surgical Procedures; Humans; Hydrocortisone; Male; Middle Aged; Neck Dissection; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
Topics: Carcinoma, Hepatocellular; Contrast Media; Drug Carriers; ErbB Receptors; Humans; Liver Neoplasms; Microspheres; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2017 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Mitochondrial Dynamics; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonamides; Breast; Caspase 3; Catalytic Domain; Cell Cycle Checkpoints; Cell Line; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Spectrum Analysis; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gold; Humans; Metal Nanoparticles; Mice; Mice, Nude; Micelles; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.
Topics: Animals; Male; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Biophysical and computational characterization of vandetanib-lysozyme interaction.
Topics: Animals; Biophysical Phenomena; Chickens; Circular Dichroism; Cluster Analysis; Enzyme Stability; Ions; Kinetics; Metals; Molecular Docking Simulation; Molecular Dynamics Simulation; Muramidase; Piperidines; Protein Structure, Secondary; Quinazolines; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2018 |
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.
Topics: Animals; Antineoplastic Agents; Autophagy; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Endothelial Cells; Glioma; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Male; Mice; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2018 |
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Topics: Adolescent; Carcinoma, Medullary; Child; Disease Progression; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Mutation, Missense; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Invasiveness; Neuroblastoma; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, CXCR4; Signal Transduction | 2018 |
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
Topics: Anilides; Humans; Mitochondria; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2018 |
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Topics: Adult; Carcinoma, Neuroendocrine; Female; Humans; Multiple Endocrine Neoplasia Type 2a; Mutation, Missense; Neoplasm Metastasis; Piperidines; Pregnancy; Quinazolines; Thyroid Neoplasms; Young Adult | 2018 |
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Corneal Diseases; Female; Humans; Male; Microscopy, Confocal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2018 |
Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
Topics: Action Potentials; Animals; Cardiotoxicity; Cardiotoxins; Electrophysiological Phenomena; ERG1 Potassium Channel; Female; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; KCNQ1 Potassium Channel; Models, Molecular; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated; Protein Kinase Inhibitors; Purkinje Fibers; Quinazolines; Rabbits | 2018 |
Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.
Topics: Adult; Antineoplastic Agents; Cicatrix; Color; Drug Eruptions; Facial Dermatoses; Female; Humans; Pigmentation Disorders; Piperidines; Quinazolines | 2018 |
Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catechin; Cell Line, Tumor; Cell Proliferation; Chemical Engineering; Drug Carriers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gold; Humans; Metal Nanoparticles; Mice, Nude; Piperidines; Porosity; Proto-Oncogene Proteins c-akt; Quinazolines; Silicon Dioxide; Tamoxifen; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2018 |
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.
Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Stomach Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, Inbred NOD; Naphthalenes; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pyrimidines; Quinazolines; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Introns; Molecular Targeted Therapy; Oncogene Addiction; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyridinium Compounds; Quinazolines; Thyroid Gland; Thyroid Neoplasms; Tissue Array Analysis; Transcription, Genetic | 2018 |
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).
Topics: Administration, Oral; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Europe; Humans; Medical Oncology; Piperidines; Placebos; Practice Guidelines as Topic; Progression-Free Survival; Quinazolines; Randomized Controlled Trials as Topic; Societies, Medical; Thyroid Neoplasms | 2018 |
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Topics: Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Child; Humans; Lung Neoplasms; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
Topics: Addison Disease; Adult; Aged; Carcinoma, Neuroendocrine; Child; Cortisone; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2019 |
RET rearrangements are actionable alterations in breast cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; NIH 3T3 Cells; Nuclear Receptor Coactivators; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; ras Guanine Nucleotide Exchange Factors; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Single-Molecule Force Measurement Guides the Design of Multivalent Ligands with Picomolar Affinity.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Ligands; Mice; Molecular Structure; Neoplasms, Experimental; Optical Imaging; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2019 |
Development of novel response surface methodology-assisted micellar enhanced synchronous spectrofluorimetric method for determination of vandetanib in tablets, human plasma and urine.
Topics: Humans; Hydrogen-Ion Concentration; Limit of Detection; Micelles; Piperidines; Quinazolines; Regression Analysis; Reproducibility of Results; Spectrometry, Fluorescence; Tablets | 2019 |
Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Topics: Anilides; Animals; Cytochrome P-450 Enzyme Inhibitors; Ellipticines; Humans; Microsomes, Liver; Oxidation-Reduction; Peroxidases; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Quinolines; Rats | 2019 |
Tyrosine Kinase Inhibitor Use and Wound Healing in Tracheoesophageal Punctures.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Esophagus; Female; Humans; Laryngectomy; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Punctures; Quinazolines; Quinolines; Speech Disorders; Surgical Wound; Thyroid Neoplasms; Trachea; Wound Healing | 2019 |
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Topics: Animals; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Mice; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Recombinant Proteins | 2019 |
Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.
Topics: Animals; Chemoembolization, Therapeutic; Doxorubicin; Drug Delivery Systems; Drug Liberation; In Vitro Techniques; Irinotecan; Liver; Liver Neoplasms; Piperidines; Quinazolines; Swine | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorophyllides; DNA Damage; DNA-Activated Protein Kinase; Down-Regulation; Drug Therapy, Combination; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Photochemotherapy; Photosensitizing Agents; Piperidines; Porphyrins; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Topics: Adult; Antineoplastic Agents; Dermatitis, Phototoxic; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2019 |
Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2.
Topics: A549 Cells; Aminoquinolines; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Conformation; Quinazolines; Quinolines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Liver Neoplasms; Piperidines; Quinazolines; Rabbits | 2019 |
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Topics: Adolescent; Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Young Adult | 2020 |
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Topics: Australia; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Precision Medicine; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines | 2019 |
Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; Oxidation-Reduction; Oxygenases; Piperidines; Quinazolines; Rats | 2020 |
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity | 2020 |
Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Necrosis; Pancreas; Pancreatitis; Paracrine Communication; Phosphatidylinositol 3-Kinase; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Resveratrol; Severity of Illness Index; Signal Transduction; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2020 |
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gene Rearrangement; Genome, Human; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Republic of Korea; Treatment Outcome | 2020 |
Oral mucosal pigmentation induced by vandetanib therapy: First clinicopathological characterization.
Topics: Aged; Biopsy; Humans; Immunohistochemistry; Male; Mouth Mucosa; Pigmentation; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2020 |
YAP confers resistance to vandetanib in medullary thyroid cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2020 |
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Chemoradiotherapy; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Topics: Adult; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Survival Analysis; Thyroid Neoplasms | 2020 |
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
Topics: Aged; Humans; Male; Nephritis, Interstitial; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2021 |
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Germ-Line Mutation; Homozygote; Humans; Male; Neurofibromatosis 1; Neurofibromin 1; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2021 |
Effects of adenosine triphosphate on vandetanib induced skin damage in rats.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Glutathione; Male; Malondialdehyde; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rats, Wistar; Skin; Skin Diseases | 2020 |
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Synergism; Female; Humans; Irinotecan; Male; Mutation; Pancreatic Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Rate; Tumor Suppressor Protein p53 | 2021 |
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Germany; Humans; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines; Registries; Retrospective Studies; Thyroid Neoplasms; Time Factors; Young Adult | 2021 |
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
Topics: Aged; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Mas; Quinazolines; Skin Neoplasms | 2020 |
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Thyroid Neoplasms | 2020 |
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; Child; Child, Preschool; Databases, Factual; Disease-Free Survival; Female; Forecasting; Humans; Infant; Infant, Newborn; Male; Middle Aged; National Health Programs; Piperidines; Quinazolines; Radiotherapy; Reoperation; Republic of Korea; Retrospective Studies; Sex Distribution; Thyroid Neoplasms; Thyroidectomy; Young Adult | 2020 |
Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2.
Topics: Cations; Creatinine; HEK293 Cells; Humans; Kidney; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Death; Cell Line; Cell Movement; Clone Cells; Diffusion; Drug Carriers; Drug Delivery Systems; Ferritins; Folic Acid; Horses; Humans; Hydrogen-Ion Concentration; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Surface Properties | 2021 |
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Topics: Angiogenesis Inhibitors; Anilides; Animals; Apoptosis; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Embryo, Nonmammalian; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms; Zebrafish | 2021 |
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib.
Topics: Apoferritins; Cell Line, Tumor; Drug Stability; Humans; Hydrogen-Ion Concentration; Nanoparticles; Piperidines; Quinazolines | 2021 |
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Liver Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factors | 2021 |
Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids.
Topics: Dasatinib; Humans; Pharmaceutical Preparations; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2021 |
Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Topics: Calibration; Dasatinib; Humans; Least-Squares Analysis; Piperidines; Quinazolines; Sorafenib; Spectrophotometry | 2022 |
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Hypopituitarism; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Medullary; Drug Approval; Humans; Mutation; Phenylurea Compounds; Piperidines; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Quinolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2021 |
A multidimensional biosensor system to guide LUAD individualized treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biosensing Techniques; Biphenyl Compounds; Cell Culture Techniques; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lignans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperidines; Precision Medicine; Quinazolines; Tumor Cells, Cultured | 2021 |
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Diarylheptanoids; Disease Models, Animal; DNA Damage; HaCaT Cells; Humans; Keratinocytes; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mitochondria; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Skin; Skin Diseases | 2021 |
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Topics: Adult; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Thyroid Neoplasms; Withholding Treatment; Young Adult | 2021 |
[Medullary thyroid carcinoma: current clinical progress].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2021 |
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2022 |
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis.
Topics: Arrhythmias, Cardiac; Down-Regulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2022 |
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Ephrins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Piperidines; Quinazolines | 2022 |